Edwards Lifesciences Corporation (ETR:EWL)
Germany
· Delayed Price · Currency is EUR 69.99
-2.51 (-3.46%)
At close: Mar 6, 2026
Edwards Lifesciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 6,068 | 5,440 | 5,010 | 4,464 | 5,233 | Upgrade
|
| Revenue Growth (YoY) | 11.55% | 8.57% | 12.23% | -14.69% | 19.29% | Upgrade
|
| Cost of Revenue | 1,334 | 1,118 | 978.4 | 722.1 | 1,249 | Upgrade
|
| Gross Profit | 4,733 | 4,322 | 4,032 | 3,742 | 3,984 | Upgrade
|
| Selling, General & Admin | 2,084 | 1,789 | 1,581 | 1,357 | 1,494 | Upgrade
|
| Research & Development | 1,079 | 1,053 | 962.9 | 843.6 | 903.1 | Upgrade
|
| Other Operating Expenses | -67.2 | -0.3 | - | - | - | Upgrade
|
| Operating Expenses | 3,096 | 2,841 | 2,544 | 2,200 | 2,397 | Upgrade
|
| Operating Income | 1,638 | 1,481 | 1,487 | 1,542 | 1,587 | Upgrade
|
| Interest Expense | -20.4 | -19.8 | -17.6 | -19.2 | -18.4 | Upgrade
|
| Interest & Investment Income | 168.8 | 120.3 | 67.2 | 35.5 | 17.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.7 | 7.1 | 10 | 1 | 5 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.5 | 6.8 | 3.4 | - | 10.8 | Upgrade
|
| EBT Excluding Unusual Items | 1,789 | 1,595 | 1,550 | 1,559 | 1,601 | Upgrade
|
| Merger & Restructuring Charges | -19.1 | -61 | - | -62.3 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -143.6 | 54.4 | -0.7 | -1.1 | -2.8 | Upgrade
|
| Asset Writedown | -40 | - | - | - | - | Upgrade
|
| Legal Settlements | -325.4 | -40.4 | -203.5 | -15.8 | -20.6 | Upgrade
|
| Other Unusual Items | 12.5 | - | 26.2 | 35.8 | 124.1 | Upgrade
|
| Pretax Income | 1,273 | 1,548 | 1,372 | 1,520 | 1,702 | Upgrade
|
| Income Tax Expense | 216.9 | 152.1 | 152.4 | 195.5 | 198.9 | Upgrade
|
| Earnings From Continuing Operations | 1,056 | 1,396 | 1,220 | 1,324 | 1,503 | Upgrade
|
| Earnings From Discontinued Operations | 13.4 | 2,774 | 179.4 | 197.9 | - | Upgrade
|
| Net Income to Company | 1,069 | 4,170 | 1,399 | 1,522 | 1,503 | Upgrade
|
| Minority Interest in Earnings | 4.1 | 4.9 | 3 | - | - | Upgrade
|
| Net Income | 1,074 | 4,175 | 1,402 | 1,522 | 1,503 | Upgrade
|
| Net Income to Common | 1,074 | 4,175 | 1,402 | 1,522 | 1,503 | Upgrade
|
| Net Income Growth | -74.28% | 197.68% | -7.85% | 1.25% | 82.55% | Upgrade
|
| Shares Outstanding (Basic) | 585 | 598 | 607 | 619 | 623 | Upgrade
|
| Shares Outstanding (Diluted) | 586 | 599 | 609 | 624 | 631 | Upgrade
|
| Shares Change (YoY) | -2.25% | -1.66% | -2.37% | -1.11% | -0.11% | Upgrade
|
| EPS (Basic) | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | Upgrade
|
| EPS (Diluted) | 1.83 | 6.97 | 2.30 | 2.44 | 2.38 | Upgrade
|
| EPS Growth | -73.70% | 202.39% | -5.44% | 2.40% | 83.08% | Upgrade
|
| Free Cash Flow | 1,335 | 289.9 | 642.8 | 973.6 | 1,406 | Upgrade
|
| Free Cash Flow Per Share | 2.28 | 0.48 | 1.05 | 1.56 | 2.23 | Upgrade
|
| Gross Margin | 78.01% | 79.46% | 80.47% | 83.82% | 76.13% | Upgrade
|
| Operating Margin | 26.99% | 27.22% | 29.69% | 34.54% | 30.32% | Upgrade
|
| Profit Margin | 17.69% | 76.75% | 27.99% | 34.09% | 28.73% | Upgrade
|
| Free Cash Flow Margin | 22.00% | 5.33% | 12.83% | 21.81% | 26.88% | Upgrade
|
| EBITDA | 1,795 | 1,624 | 1,609 | 1,681 | 1,721 | Upgrade
|
| EBITDA Margin | 29.58% | 29.85% | 32.12% | 37.67% | 32.90% | Upgrade
|
| D&A For EBITDA | 156.6 | 143.2 | 122 | 139.6 | 134.8 | Upgrade
|
| EBIT | 1,638 | 1,481 | 1,487 | 1,542 | 1,587 | Upgrade
|
| EBIT Margin | 26.99% | 27.22% | 29.69% | 34.54% | 30.32% | Upgrade
|
| Effective Tax Rate | 17.04% | 9.83% | 11.11% | 12.87% | 11.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.